


207535772

1AP20 Rec'd PTO 12 JUL 2006

PATENT

ATTORNEY DOCKET NO. 50120/008001

Certificate of Mailing	
Date of Deposit: <u>July 12, 2006</u>	Label Number: <u>EV768765377US</u>
I hereby certify under 37 C.F.R. § 1.10(a) that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
<u>Elvis De La Cruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Young et al.	Confirmation No.:	Not yet assigned
Serial No.:	Not yet assigned	Art Unit:	Not yet assigned
Filed:	July 12, 2006	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a Sequence Listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.824 and consisting of 26 pages.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the

Sequence Listing, and each sequence in the Sequence Listing is assigned a separate
sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout
the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the
Sequence Listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the
computer readable form of the Sequence Listing are the same as the contents of the paper
copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains
no new matter.

If there are any charges or any credits, please apply them to Deposit Account
No. 03-2095.

Respectfully submitted,

Date: 12 July 2006

 FOR KAREN L. ELBING
Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109
REG NO 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045